Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096304 · ClinicalTrials.gov registry record · Phase 1
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00096304: Clinical Trial Phase 1 study, sponsored by Medical University of South Carolina.
NCT00096304 is a Phase 1 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096304, a Phase 1 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.
Interventions
- DRUG docetaxel
- DRUG epirubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-06-08 |
| Est. Completion | 2007-11-30 |
| Phase | Phase 1 |
Why NCT00096304 stopped before completion
NCT00096304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00096304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096304 about?
NCT00096304 is a clinical study titled "Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin...
What is the current status of trial NCT00096304?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-06-08. Estimated completion is 2007-11-30.
What interventions are being tested in trial NCT00096304?
The interventions under investigation include: docetaxel (DRUG), epirubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00096304?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00096304's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI